The Price Target For Citius Pharmaceuticals Inc. (CTXR)?

0
6
KOSK
KOSK

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) finished Thursday with a subtraction of -$0.01 to close at $1.16, a downside of -0.85 percent. An average of 494,011 shares of common stock have been traded in the last five days. There was a fall of -$0.1050 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 488,768 shares traded, while the 50-day average volume stands at 626,989.

CTXR stock has decreased by -4.10% in the last month. The company shares reached their 1-month lowest point of $1.1200 on 09/23/22. With the stock rallying to its 52-week high on 04/06/22, shares of the company touched a low of $0.83 and a high of $2.25 in 52 weeks. It has reached a new high 8 times so far this year and lost -24.03% or -$0.3950 in price. In spite of this, the price is down -48.44% from the 52-week high.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Valuation Metrics

Citius Pharmaceuticals Inc. (CTXR) stock’s beta is 1.32. Other valuation ratios to consider include the price-to-book (PB) ratio at 1.56.

Financial Health

The quick ratio of Citius Pharmaceuticals Inc. for the three months ended June 29 was 11.40, and the current ratio was 11.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $11000.0 compared to revenue of $23.53 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Citius Pharmaceuticals Inc.’s return on assets was -23.20%.

Earnings Surprise

For the three-month period that ended June 29, Citius Pharmaceuticals Inc. had $40000.0 in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$8.86 million in the quarter, while revenues of -$7.56 million were grew 17.95%. The analyst consensus anticipated Citius Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.05 per share, but it turned out to be -$0.06, a -20.00% surprise. For the quarter, EBITDA amounted to -$8.87 million. Shareholders own equity worth $146.13 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Citius Pharmaceuticals Inc. (CTXR) price momentum. RSI 9-day as of the close on 22 September was 35.06%, suggesting the stock is Neutral, with historical volatility in this time frame at 33.67%.

As of today, CTXR’s price is $1.2050 -8.40% or -$0.1050 from its 5-day moving average. CTXR is currently trading -10.55% lower than its 20-day SMA and +18.78% higher than its 100-day SMA. However, the stock’s current price level is +27.95% above the SMA50 and -37.77% below the SMA200.

The stochastic %K and %D were 25.43% and 29.64%, respectively, and the average true range (ATR) was 0.0774. With the 14-day stochastic at 9.62% and the average true range at 0.0769, the RSI (14) stands at 42.98%. The stock has reached -0.0456 on the 9-day MACD Oscillator while the 14-day reading was at -0.0685.

Analyst Ratings

Maxim Group launched coverage on Citius Pharmaceuticals Inc. (NASDAQ: CTXR) in its analyst report released on November 30, 2021. The firm assigned the stock a Buy rating. The consensus rating for Citius Pharmaceuticals Inc. (CTXR) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CTXR, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.

What is CTXR’s price target for the next 12 months?

Analysts predict a range of price targets between $4.00 and $10.00, with a median target of $7.00. Taking a look at these predictions, the average price target given by analysts for Citius Pharmaceuticals Inc. (CTXR) stock is $7.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here